Kalogirou EM, Katsoulas N, Tosios KI, Lazaris AC, Sklavounou A. Non-healing tongue ulcer in a rheumatoid arthritis patient medicated with leflunomide. An adverse drug event? J Clin Exp Dent. 2017;9(2):e325-8.

doi:10.4317/jced.53428

http://dx.doi.org/doi:10.4317/jced.53428

References

1. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arth Rheumatol. 1999;42:1322-8. https://doi.org/10.1002/1529-0131(199907)42:7<1322::AID-ANR4>3.0.CO;2-P PMid: 10403258

2. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999;93:198-208. https://doi.org/10.1006/clim.1999.4777 PMid:10600330

3. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthr Rheumatol. 2001;44:1984-92. https://doi.org/10.1002/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B PMid: 11592358

4. Knab J, Goos M, Dissemond J. Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy. J Eur Acad Dermatol Venereol. 2005;19:243-6. https://doi.org/10.1111/j.1468-3083.2005.01118.x PMid:15752303

5. Di Nuzzo S, Zanni M, De Panfilis G. Cutaneous ulceration induced by leflunomide in a psoriatic patient. Int J Dermatol. 2009;48:666-8. https://doi.org/10.1111/j.1365-4632.2009.03981.x PMid:19538387

6. Jakob A, Porstmann R, Rompel R. Skin ulceration after leflunomide treatment in two patients with rheumatoid arthritis. J Deutsch Dermatol Gesellschaft. 2006;4:324-7. https://doi.org/10.1111/j.1610-0387.2006.05934.x PMid:16638062

7. Yoo HG, Yu HM, Jun JB, Jeon HS, Yoo WH. Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. Mod Rheumatol. 2013;23:709-15. https://doi.org/10.3109/s10165-012-0716-8 PMid:22791271

8. Mays JW, Sarmadi M, Moutsopoulos NM. Oral manifestations of systemic autoimmune and inflammatory diseases: diagnosis and clinical management. J Evid-Bas Dent Pract. 2012;12:265-82. https://doi.org/10.1016/S1532-3382(12)70051-9 PMid: 23040353

9. Neville BW, Damm DD, Allen CM, Bouquot J. Oral and Maxillofacial Pathology. 3rd ed. St. Louis: Saunders Elsevier; 2009.

10. Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Letters. 1993;334:61-4. https://doi.org/10.1016/0014-5793(93)81704-4 PMID: 8224241

11. Kalantzis A, Marshman Z, Falconer DT, et al. Oral effects of low-dose methotrexate treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2005;100:52-62. https://doi.org/10.1016/j.tripleo.2004.08.020 PMid:15953917